Emerging in the landscape of excess body fat therapy, retatrutide represents a distinct method. Beyond many available medications, retatrutide functions as a double agonist, concurrently targeting both GLP peptide-1 (GLP-1) and glucose-responsive insulinotropic substance (GIP) binding sites. The dual stimulation promotes several beneficial effects,